Effects of trolox, locally applied on round windows, on cisplatin-induced ototoxicity in guinea pigs

International Journal of Pediatric Otorhinolaryngology

Volumn 67, Issue 2, 2003, Pages 133-139

  Teranishi, Masa Aki ^a   Nakashima, Tsutomu ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Guinea pigs; Ototoxicity; Round windows; Trolox

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; CISPLATIN; TROLOX C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; COCHLEA FENESTRA; CONTROLLED STUDY; DRUG EFFECT; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR CELL; HUMAN; LIPID SOLUBILITY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; AUDITORY THRESHOLD; CHROMANS; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; EAR, MIDDLE; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GUINEA PIGS; HEARING LOSS, SENSORINEURAL; PROBABILITY; RANDOM ALLOCATION; REFERENCE VALUES; RISK ASSESSMENT; ROUND WINDOW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0037294899     PISSN: 01655876     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5876(02)00353-1     Document Type: Article

References (48)

1. Coupland S.G., Ponton C.W., Eggermont J.J., Bowen T.J., Grant R.M. Assessment of cisplatin-induced ototoxicity using derived-band ABRs. Int. J. Pediatr. Otorhinolaryngol. 22:1991;237-248.
2. Berg A.L., Spitzer J.B., Garvin J.H. Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 109:1999;1806-1814.
3. Stavroulaki P., Apostolopoulos N., Segas J., Tsakanikos M., Adamopoulos G. Evoked otoacoustic emissions - an approach for monitoring cisplatin induced ototoxicity in children. Int. J. Pediatr. Otorhinolaryngol. 59:2001;47-57.
4. Schaefer S., Post J.D., Close L.O., Wright C.O. Ototoxicity of low and moderate dose cis-platinum. Cancer. 56:1985;1934-1939.
5. Ozols R.F., Young R.C. High-dose cisplatin therapy in ovarian cancer. Semin. Oncol. 12:(Suppl. 6):1985;21-30.
6. Stewart D.J., Verma S., Maroun J.A. Phase I study of the combination of disulfiram with cisplatin. Am. J. Clin. Oncol. 10:1987;517-519.
7. Stoter G., Koopman A., Vendrik C.P., Struyvenberg A., Sleyfer D.T., Willemse P.H., Schraffordt K.H., van Oasterom A.T., ten Bokkel Huinink W.W., Pinedo H.M. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine and bleomycin. J. Clin. Oncol. 7:1989;1099-1104.
8. Gandara D.R., Wiebe V.J., Perez E.A., Makuch R.W., deGregorio M.W. Cisplatin rescue therapy: experience with sodium thiosulphate, WR-2721, and diethyldithiocarbamate. Crit. Rev. Oncol. Hematol. 10:1990;353-365.
9. Church M.W., Kaltenbach J.A., Blakley B.W., Burgio D.L. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hearing Res. 86:1995;195-203.
10. Campbell K.C.M., Rybak L.P., Meech R.P., Hughes L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hearing Res. 102:1996;90-98.
11. Strauss M., Towfighi J., Lord S., Lipton A., Harvey H.A., Brown B. Cis-platinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope. 93:1983;1554-1559.
12. Fleischman R.W., Standnicki S.W., Ethier M., Schaeppi U. Ototoxicity of cis-diammindichloroplatinum II in the guinea pig. Toxicol. Appl. Pharmacol. 33:1975;320-332.
13. Barron S.E., Daigneault E.A. Effect of cisplatin on hair cell morphology and lateral wall Na, K-ATPase activity. Hearing Res. 26:1987;131-137.
14. McAlpine D., Johnstone B.M. The ototoxic mechanism of cisplatin. Hearing Res. 47:1990;191-204.
15. Fernandez-Cervilla F., Crespo P.V., Ciges M., Campos A. Early morphofunctional alterations induced by cisplatin in the cochlea. A quantitative and electrocochleographic study. Otorhinolaryngolgy. 55:1993;337-340.
16. Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 103:1993;1-52.
17. Brock P., Pritchard J., Bellman S., Pinkerton C.R. Ototoxicity of high-dose cis-platinum in children. Med. Pediatr. Oncol. 16:1988;368-380.
18. Skinner R., Pearson A.D.J., Amineddine H.A., Mathias D.B., Craft A.W. Ototoxicity of cisplatinum in children and adolescents. Br. J. Cancer. 61:1990;927-931.
19. McHaney V.A., Thibadoux G., Hayes F.A., Green A.A. Hearing loss in children receiving cisplatin chemotherapy. J. Pediatr. 102:1983;314-317.
20. Ravi R., Somani S.M., Rybak L.P. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol. Toxicol. 76:1995;386-394.
21. Rybak L.P., Ravi R., Somani S.M. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam. Appl. Toxicol. 26:1995;293-300.
22. Rybak L.P., Husain K., Evenson L., Morris C., Whitworth C., Somani S.M. Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system. Pharmacol. Toxicol. 81:1997;173-179.
23. Rybak L.P., Husain K., Whitworth C., Somani S.M. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol. Sci. 47:1999;195-202.
24. Teranishi M., Nakashima T., Wakabayashi T. Effects of α-tocopherol on cisplatin-induced ototoxicity in guinea pigs. Hearing Res. 151:2001;61-70.
25. Barclay L.R.C., Locke S.J., MacNeil J.M., VanKessel J. Autoxidation of micelles and model membranes. Quantitative kinetic measurements can be made by using either water-soluble or lipid-soluble initiators with water-soluble or lipid-soluble chain-breaking antioxidants. J. Am. Chem. Soc. 106:1984;2479-2481.
26. Garetz S.L., Rhee D.J., Schacht J. Sulfhydryl compounds and antioxidants inhibit cytotoxicity to outer hair cells of a gentamicin metabolite in vitro. Hearing Res. 77:1994;75-80.
27. Attanasio G., Spongr V.P., Henderson D. Localization of F-actin and fodrin along the organ of Corti in the chinchilla. Hearing Res. 81:1994;199-207.
28. Raphael Y., Athey B.D., Wang Y., Lee M.K., Altschuler R.A. F-actin, tubulin and spectrin in the organ of Corti: comparative distribution in different cell types and mammalian species. Hearing Res. 76:1994;173-187.
29. Nair T.S., Prieskorn D.M., Miller J.M., Dolan D.F., Raphael Y. KHRI3 monoclonal antibody-induced damage to the inner ear: antibody staining of nascent scars. Hearing Res. 129:1999;50-60.
30. Saito T., Manabe Y., Honda N., Yamada T., Yamamoto T., Saito H. Semiquantitative analysis by scanning electron microscopy of cochlear hair cell damage by ototoxic drugs. Scanning Microsc. 9:1995;271-281.
31. O'Leary S.J., Klis S.F.L., de Groot J.C.M.J., Hamers F.P.T., Smoorenburg G.F. Perilymphatic application of cisplatin over several days in albino guinea pigs: dose-dependency of electrophysiological and morphological effects. Hearing Res. 154:2001;135-145.
32. Di Re F., Bohm S., Oriana S., Spatti G.B., Pirovano C., Tedeschi M., Zunino F. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann. Oncol. 4:1993;55-61.
33. Kopke R.D., Liu W., Gabaizadeh R., Jacono A., Feghali J., Spray D., Garacia P., Steinman H., Malgrange B., Ruben R.J., Rybak L., Van de Water T.R. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otol. 18:1997;559-571.
34. Walker M.E. Jr., Fazekas-May A.M., Heard W.K., Yee S., Montague D., Jones M.M. Prevention of cisplatin-induced toxicity by selected dithiocarbamates. Ann. Clin. Lab. Sci. 24:1994;121-133.
35. Kaltenbach J.A., Church M.W., Blakley B.W., McCaslin D.L., Burgio D.L. Comparion of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otorhinolaryngol. Head Neck Surg. 117:1997;493-500.
36. J.S. Rubin, S. Wadler, J.J. Beitler, H. Haynes, A. Rozenblet, F. McGill, G. Goldberg, C. Runowicz, Audiological findings in a phase I protocol investigating the effect of WR-2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma, J. Laryngol. Otol. 109, 744-747.
37. Gabaizadeh R., Staecker H., Liu W., Kopke R., Malgrange B., Lefebvre P.P., Van de Water T.R. Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Acta Otolaryngol. (Stockh.). 117:1997;232-238.
38. Campbell G.W., Meech R.P., Rybak L.P., Hughes L.F. D-methionine protects against cisplatin damage to the stria vascularis. Hearing Res. 138:1999;13-28.
39. Li G., Frenz D.A., Brahmblatt S., Feghali J.G., Ruben R.J., Berggren D., Arezzo J., Van De Water T.R. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology. 22:2001;163-176.
40. Kamimura T., Whitworth C.A., Rybak L.P. Effects of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hearing Res. 131:1999;117-127.
41. Rybak L.P., Whitworth C., Somani S.M. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope. 109:1999;1740-1744.
42. Marubayashi S., Dohi K., Ochi K., Kawasaki T. Role of free radicals in ischemic rat liver cell injury: prevention of damage by α-tocopherol administration. Surgery. 99:1986;184-191.
43. Lautermann J., Crann S.A., Mc Laren J., Shacht J. Glutathione-dependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise. Hearing Res. 114:1997;75-82.
44. Castle L., Perkins M.J. Inhibition kinetics of chain-breaking phenolic antioxidants in SDS micelles. Evidence that intermicellar diffusion rates may be rate-limiting for hydrophobic inhibitors such as α-tocopherol. J. Am. Chem. Soc. 108:1986;6381-6382.
45. Laurell G., Andersson A., Engström B., Ehrsson H. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother. Pharmacol. 36:1995;83-86.
46. Nedzelski J.M., Chiong C.M., Fradet G., Schessel D.A., Bryce G.E., Pfeiderer A.G. Intratympanic gentamicin instillation as treatment of unilateral Meniere's disease: update of an ongoing study. Am. J. Otol. 14:1993;278-282.
47. Rauch S.D., Oas J.G. Intratympanic gentamicin for treatment of intractable Meniere's disease: a preliminary report. Laryngoscope. 107:1997;49-55.
48. Ödkvist L.M., Bergenius J., Möller C. When and how to use gentamicin in the treatment of Meniere's disease. Acta Otolaryngol. (Stockh.). 526:1997;54-57.